Technical feasibility for the Revive + Adrenaline Auto-injector

Abstract

An adrenaline auto-injector (AAI) is prescribed to people who are susceptible to severe allergies that put them at risk of anaphylaxis -- a life threatening allergic reaction. Despite medical advice to carry the injector on person at all times, our user studies show:

1. People do not carry them nearly as much as they should
2. Not receiving adrenaline for an anaphylactic reaction is the biggest common factor in fatalities as adrenaline is the only drug known to prevent death due to anaphylaxis.

Revive is a new AAI concept developed as a graduation project at the Royal College of Art (RCA). This project seeks to extend the promising results of this prior phase wherein a proof of concept(PoC) was developed. Designed with the patient at its centre, it's much smaller size makes it easy to carry and its form makes it discreetly fit within a patient's life. These combine like never before to counteract the identified problems of being too large to practically carry continuously and adverse impacts on quality of life from an obvious medical form and associated stigma. Revive achieves this through a fresh examination of how a syringe should be designed for an AAI. The proprietary needle injection system concept has been awarded InnovationRCA's support and is patent pending in the UK.

We have developed a PoC where we tested functionality and medicine dosage. Revive also has simplified instructions designed to improve accurate use. Revive, unlike most current offerings in the market, incorporates a variety of needle lengths.

Now, the team seeks to extend this achievement by conducting a technical feasibility study through the engineering audit of the concept.

Lead Participant

Project Cost

Grant Offer

Revive Innovations + Limited £272,386 £ 190,670

Publications

10 25 50